The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
May 25th 2023
An analysis of data from the ARIC study is offering new insight into the impact of age at diabetes onset on the risk of developing dementia later in life.
Need for Increased Screening and Clinician Education, and Greater Awareness of Clinical Trial OpportunitiesFebruary 6th 2023
Drs Diana Isaacs and Natalie Bellini highlight the need for improved screening, greater awareness of clinical trial opportunities, and clinician education to improve early diagnosis and outcomes for people with T1D.
Impact of New Treatment Approval and Other Advances on the Type 1 Diabetes Patient CommunityFebruary 6th 2023
Sumita Singh, a T1D advocate, discusses with Diana Isaacs and Natalie Bellini how teplizumab and other advances are providing hope to the T1D community and talks about the challenges and needs of a diverse T1D patient population.
Challenges in Diagnosing Type 1 DiabetesFebruary 6th 2023
Sumita Singh shares about her daughter Bella’s type 1 diabetes (T1D) diagnosis and how their family navigated the logistical and emotional challenges of receiving a T1D diagnosis.
Assisted Reproductive Technology Use Has Little Impact on Long-Term Cardiometabolic Health in OffspringFebruary 6th 2023
An analysis of more than a dozen cohort studies containing data from more than 30,000 offspring provides clinicians with the most detailed overview yet of differences in cardiometabolic health outcomes in those conceived naturally compared to those conceived with use of assisted reproductive technologies.
Endocrine Case Report: Elbow PainFebruary 5th 2023
Our latest endocrine case report from Brady Pregerson, MD, features a patient in their mid-60’s presenting to the hospital with approximately 2 days of gradually worsening right elbow pain. Can you determine the correct diagnosis?
Challenges in Managing Type 1 Diabetes and Pressing Need for New TherapiesFebruary 3rd 2023
Drs Diana Isaacs and Natalie Bellini discuss the everyday challenges of managing type 1 diabetes and underscore the need for new treatments to improve the quality of life for people living with type 1 diabetes
Study Design and Key Findings from Teplizumab Clinical Trials in Type 1 DiabetesFebruary 3rd 2023
Dr Emily Sims reviews the study design of the clinical trials with teplizumab and shares key findings from the completed phase 2 trial.
Stages of Type 1 Diabetes and Mechanism of Action of TeplizumabFebruary 3rd 2023
Dr Emily Sims provides an overview of the stages of type 1 diabetes (T1D) and explains how teplizumab slows the immune-mediated destruction of beta cells.
Plateauing Cardiovascular Disease Rates in Type 2 Diabetes Concealing Growing Income-Based Disparities, Study FindsFebruary 1st 2023
Research from investigators in Ontario, Canada suggests the plateau in rates of cardiovascular disease and hospitalizations among people with type 2 diabetes seen in the last decade is masking a growing income-based disparity.
Endocrine Month in Review: January 2023January 31st 2023
The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.
Comprehensive Study, Boasting 40 Years of Follow-up, Underlines Long-Term Benefits of Bariatric SurgeryJanuary 25th 2023
With up to 40 years of follow-up, a retrospective study of matched pairs is providing an overview of the long-term risks and benefits of bariatric surgery in people with overweight or obesity.
Advanced Hybrid Closed Loop System Could Improve Glucose Control in Youth with High-Risk Type 1 DiabetesJanuary 24th 2023
A prospective, dual-center study of people with high-risk type 1 diabetes using multiple daily injections aged 13-25 years demonstrates the utility of this technology in this patient population.
Bexagliflozin (Brenzavvy) Receives FDA Approval for Type 2 Diabetes in AdultsJanuary 23rd 2023
Announced on January 23, the US FDA's approval of bexagliflozin (Brenzavvy) was awarded to TheracosBio and indicates the SGLT2 inhibitor for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Cost Among Key Concerns for People with Diabetes Choosing a Glucose MonitorJanuary 18th 2023
The uptake of modern glucose-monitoring technologies for people with T1D and T2D may be dependent on out-of-pocket costs, suggesting the need to reconsider cost-benefit profiles of these devices.
Noninvasive CT Scan Could Identify Primary Aldosteronism Patients Eligible for AdrenalectomyJanuary 17th 2023
Comparing MTO scanning against adrenal vein sampling, investigators in the UK found the noninvasive diagnostic option could improve the identification of primary aldosteronism and candidates for adrenalectomy.
Anti-VEGF Use for Diabetic Eye Diseases Increased 200% in Last DecadeJanuary 16th 2023
An analysis of a commercial claims database offers insight into the increase in vision-threatening eye disease among people with diabetes aged younger than 65 years from 2009-2018, with results also detailing trends in anti-VEGF therapy during the same period.
Coffee Consumption Linked to Lower Severity of NAFLD in Type 2 DiabetesJanuary 13th 2023
A study examining associations between coffee metabolites and risk of NAFLD severity suggests people with type 2 diabetes had a lower risk of fibrosis and more severe NAFLD based on increased coffee consumption.
FDA Updates Label for Oral Semaglutide, Making Agent a First-Line Therapy in Type 2 DiabetesJanuary 13th 2023
Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.
Rates of Type 1, Type 2 Diabetes Expected to Balloon in US by 2060January 12th 2023
Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.